Therapeutic Targeting of Decr1 Ameliorates Cardiomyopathy by Suppressing Mitochondrial Fatty Acid Oxidation in Diabetic Mice
Journal of Cachexia, Sarcopenia and Muscle · 2025-04 · 16 (2)
DOI: 10.1002/jcsm.13761 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cachexia, Sarcopenia and Muscle, online erschienen am 07.03.2025. Verfasst von Qing-Bo Lu und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Affiliated Hospital of Jiangnan University, Jiangnan University, Wuxi, Jiangsu, China. Hauptthemen laut MEDLINE: Diabetic Cardiomyopathies, Fatty Acids, Diabetes Mellitus, Experimental, Mitochondria. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Jiangsu Province Excellent Youth Fund, Jiangsu Natural Science Foundation.
Abstract (Originalsprache)
Background
A significant increase in mitochondrial fatty acid oxidation (FAO) is now increasingly recognized as one of the metabolic alterations in diabetic cardiomyopathy (DCM). However, the molecular mechanisms underlying mitochondrial FAO impairment in DCM remain to be fully elucidated.
Methods
A type 2 diabetes (T2D) mouse model was established by a combination of high‐fat diet (HFD) and streptozotocin (STZ) injection. Neonatal rat cardiomyocytes were treated with high glucose (HG) and palmitic acid (HP) to simulate diabetic cardiac injury. Gain‐ and loss‐of‐function approaches and RNA sequencing were utilized to investigate the role and mechanism of 2,4‐dienoyl‐CoA reductase 1 (Decr1) in DCM.
Results
By integrating the genomic data available in the Gene Expression Omnibus (GEO) with DCM rodents, we found that the transcriptional level of Decr1 was consistently upregulated in DCM (+255% for diabetic heart, p < 0.0001; +281% for diabetic cells, p < 0.0001). Cardiomyocytes‐specific knockdown of Decr1 preserved cardiac function (+41% for EF, p < 0.0001; +24% for FS, p = 0.0052), inhibited cardiac hypertrophy (−34%, p < 0.0001), fibrosis (−69%, p < 0.0001), apoptosis (−56%, p < 0.0001) and oxidative damage (−59%, p < 0.0001) in DCM mice, while cardiomyocytes‐specific overexpression of Decr1 aggravated DCM (−28% for EF, p = 0.0347; −17% for FS, p = 0.0014). Deletion of Decr1 prevented high glucose/palmitate (HG/HP)‐induced hypertrophy (−22%, p = 0.0006), mitochondrial dysfunction and apoptosis (−74%, p < 0.0001) in cultured cardiomyocytes. Furthermore, RNA sequencing and functional analysis showed that Decr1 interacted with and upregulated pyruvate dehydrogenase kinase 4 (PDK4) in injured cardiomyocytes, and overexpression of PDK4 eliminated the benefits of Decr1 downregulation in DCM (−20% for EF, p = 0.0071; −28% for FS, p = 0.0022). Mechanistically, PDK4 acted as a kinase that induced phosphorylation and mitochondrial translocation of HDAC3. In the mitochondria, HDAC3 mediated the deacetylation of dehydrogenase trifunctional multienzyme complex α subunit (HADHA), contributing to excessive mitochondrial FAO and subsequent cardiac injury. From a screening of 256 natural products, we identified Atranorin and Kurarinone as potential inhibitors of Decr1, both demonstrating protective effects against DCM (Atranorin, +21% for EF, p = 0.0134; +24% for FS, p = 0.0006; Kurarinone, +20% for EF, p = 0.0183; +27% for FS, p = 0.0001).
Conclusions
Our study delineates a molecular mechanism by which Decr1 potentiated higher mitochondrial lipid oxidation and cardiac damage by enhancing HADHA deacetylation through the PDK4/HDAC3 signalling pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Affiliated Hospital of Jiangnan University, Jiangnan University, Wuxi, Jiangsu, China.
- School of Pharmacy, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Minis…
- Department of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing Medical University, Nanjing, China.
- Department of Anesthesiology, Affiliated Hospital of Jiangnan University, Jiangnan University, Wuxi, China.
- MOE Medical Basic Research Innovation Center for Gut Microbiota and Chronic Diseases, School of Medicine, Jiangnan University, Wuxi, China.
- Research Institute for Reproductive Health and Genetic Diseases, Wuxi Maternity and Child Health Care Hospital, Jiangnan University, Wuxi, China.
ORCID-Profile: Hai-Jian Sun
Förderung
- National Natural Science Foundation of China
- Jiangsu Province Excellent Youth Fund
- Jiangsu Natural Science Foundation
- Fundamental Research Funds for the Central Universities
- Jiangnan University
- Wuxi Science and Technology Development Fund
- Wuxi Municipal Health Commission Youth Project
- Wuxi Health Committee
Zitieren
APA
Lu, Q. B., Sun, H. T., Zhou, K., Su, J. B., Meng, X. Y., Chen, G., Zhang, A. Y., Xu, A. J., Zhao, C. Y., Zhang, Y., Wang, Y., Qiu, H. B., Lv, Z. L., Bao, Z. Y., Zhu, J., Xiao, F., Zhu, X. X., & Sun, H. J. (2025). Therapeutic Targeting of Decr1 Ameliorates Cardiomyopathy by Suppressing Mitochondrial Fatty Acid Oxidation in Diabetic Mice. Journal of Cachexia, Sarcopenia and Muscle, 16(2). https://doi.org/10.1002/jcsm.13761
Vancouver
Lu QB, Sun HT, Zhou K, Su JB, Meng XY, Chen G, et al. Therapeutic Targeting of Decr1 Ameliorates Cardiomyopathy by Suppressing Mitochondrial Fatty Acid Oxidation in Diabetic Mice. Journal of Cachexia, Sarcopenia and Muscle. 2025;16(2). doi:10.1002/jcsm.13761
BibTeX
@article{Lu2025,
author = {Lu, Qing-Bo and Sun, He-Ting and Zhou, Kuo and Su, Jia-Bao and Meng, Xin-Yu and Chen, Guo and Zhang, Ao-Yuan and Xu, An-Jing and Zhao, Chen-Yang and Zhang, Yuan and Wang, Yao and Qiu, Hong-Bo and Lv, Zhuo-Lin and Bao, Zheng-Yang and Zhu, Jian and Xiao, Feng and Zhu, Xue-Xue and Sun, Hai-Jian},
title = {Therapeutic Targeting of Decr1 Ameliorates Cardiomyopathy by Suppressing Mitochondrial Fatty Acid Oxidation in Diabetic Mice},
journal = {Journal of Cachexia, Sarcopenia and Muscle},
year = {2025},
volume = {16},
number = {2},
doi = {10.1002/jcsm.13761}
}
EUVIMED